Lidocaine/prilocaine spray for premature ejaculation

  title={Lidocaine/prilocaine spray for premature ejaculation},
  author={Dtb Cmecpd},
  journal={Drug and Therapeutics Bulletin},
  pages={45 - 48}
  • Dtb Cmecpd
  • Published 2017
  • Medicine
  • Drug and Therapeutics Bulletin
Although premature ejaculation is the most common ejaculation problem, it is poorly understood and currently has no standard definition.1 Typically, it involves reduced time to ejaculation, inability to control or delay ejaculation and associated distress.1-5 Treatments that have been assessed include psychosexual counselling, antidepressants (e.g. selective serotonin reuptake inhibitors), phosphodiesterase type-5 inhibitors, tramadol and topical anaesthetic agents (e.g. lidocaine/prilocaine… Expand
2 Citations
Fortacin™ Spray for the Treatment of Premature Ejaculation
The metered-dose spray delivery system allows the desensitizing agents to be deposited in a dose-controlled, concentrated film onto the glans penis consequently reducing its sensitivity, translating into a delaying of the ejaculatory latency time without adversely affecting the sensation of ejaculation and orgasmic pleasure. Expand
Topical Treatment of Premature Ejaculation: The Rise of Anesthetic Spray Formulations?
A narrative review to summarize the most recent findings regarding the use of topical treatments for PE found topical anesthetics have proved to increase ejaculatory latency, control, and sexual satisfaction in couple affected by PE with limited rates of adverse events. Expand


Medical therapy for premature ejaculation
Dapoxetine, which is a on-demand SSRI, is the only licensed drug for the treatment of PE, increasing IELT by a factor of 2.5 to 3 with limited and tolerable side effects. Expand
Current Diagnosis and Management of Premature Ejaculation
Premature ejaculation (PE) is a common sexual dysfunction characterized by reduced intravaginal ejaculatory latency time (IELT), inability to delay ejaculation, and personal distress. IncreasingExpand
Emerging and investigational drugs for premature ejaculation
  • C. McMahon
  • Medicine
  • Translational andrology and urology
  • 2016
Current data on the treatment of PE was reviewed and critiqued using the principles of evidence-based medicine and new on-demand rapid acting SSRIs, oxytocin receptor antagonists, or single agents that target multiple receptors may form the foundation of more effective future on- demand medication. Expand
Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment - topical versus systemic.
  • Á. Morales
  • Medicine
  • Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • 2012
Evidence demonstrated that PSD502, dapoxetine and other SSRIs all significantly improve the symptoms of PE, and systemic use of SSRIS presents risks associated with the known pharmacology of this class. Expand
Update on treatments for premature ejaculation
  • W. Hellstrom
  • Medicine
  • International journal of clinical practice
  • 2011
Current and upcoming treatment options for premature ejaculation (PE) are of global clinical interest and it is hoped that these newer agents will improve the quality of life for patients who suffer from PE. Expand
Dapoxetine for premature ejaculation
  • C. McMahon
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2010
Dapoxetine, as the first drug developed for PE, is an effective and safe treatment for PE and represents a major advance in sexual medicine. Expand
Topical anaesthetics for premature ejaculation: a systematic review and meta-analysis.
Topical anaesthetics appear more effective than placebo, paroxetine and sildenafil at increasing IELT in men with PE, however, the methodological quality of the existing RCT evidence base is uncertain. Expand
PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double‐blind, placebo‐controlled study
To determine the effect of PSD502 applied topically 5 min before intercourse on the Index of Premature Ejaculation (IPE) and intravaginal ejaculatory latency time (IELT) of men with lifelongExpand
Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study.
In this study, PSD502 applied topically to the glans penis 5 minutes before intercourse showed significantly improved ejaculatory latency, ejaculatory control, sexual satisfaction and distress and was shown to be well tolerated by patients and partners. Expand
Behavioral Therapies for Management of Premature Ejaculation: A Systematic Review
There is limited evidence that physical behavioral techniques for PE improve IELT and other outcomes over waitlist and that behavioral therapies combined with drug treatments give better outcomes than drug treatments alone. Expand